Sionna Therapeutics (NASDAQ:SION) Hits New 12-Month High – Should You Buy?

Sionna Therapeutics, Inc. (NASDAQ:SION)’s stock price hit a new 52-week high on Saturday . The company traded as high as $51.00 and last traded at $49.41, with a volume of 1139291 shares. The stock had previously closed at $45.29.

Wall Street Analyst Weigh In

SION has been the subject of several recent analyst reports. Citizens Jmp reiterated a “market outperform” rating and set a $63.00 price target on shares of Sionna Therapeutics in a research note on Tuesday, May 26th. BTIG Research reissued a “buy” rating and issued a $58.00 price objective on shares of Sionna Therapeutics in a research note on Wednesday, May 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Sionna Therapeutics in a report on Friday, May 8th. Wall Street Zen cut Sionna Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Finally, Freedom Capital downgraded Sionna Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, May 20th. Three equities research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $53.22.

Sionna Therapeutics Trading Up 9.1%

The stock has a market cap of $2.23 billion, a P/E ratio of -25.60 and a beta of 1.33. The firm’s fifty day moving average is $40.74 and its 200 day moving average is $39.63.

Sionna Therapeutics (NASDAQ:SION) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.08). Research analysts forecast that Sionna Therapeutics, Inc. will post -2.57 earnings per share for the current fiscal year.

Insider Activity

In other Sionna Therapeutics news, Director Orbimed Advisors Llc sold 184,639 shares of the firm’s stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $46.22, for a total value of $8,534,014.58. Following the sale, the director owned 2,671,822 shares of the company’s stock, valued at $123,491,612.84. This trade represents a 6.46% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Peter A. Thompson sold 184,639 shares of Sionna Therapeutics stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $46.22, for a total value of $8,534,014.58. Following the completion of the transaction, the director directly owned 2,671,822 shares in the company, valued at approximately $123,491,612.84. This represents a 6.46% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 989,630 shares of company stock valued at $44,987,483 in the last three months. 5.10% of the stock is owned by insiders.

Institutional Investors Weigh In On Sionna Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of SION. Viking Global Investors LP raised its stake in Sionna Therapeutics by 8.2% during the 2nd quarter. Viking Global Investors LP now owns 3,195,181 shares of the company’s stock valued at $55,436,000 after purchasing an additional 242,427 shares during the last quarter. Jennison Associates LLC grew its position in Sionna Therapeutics by 30.1% in the 1st quarter. Jennison Associates LLC now owns 1,451,220 shares of the company’s stock worth $58,179,000 after purchasing an additional 335,942 shares during the last quarter. Vanguard Group Inc. grew its position in Sionna Therapeutics by 3.7% in the 4th quarter. Vanguard Group Inc. now owns 1,184,951 shares of the company’s stock worth $48,749,000 after purchasing an additional 41,797 shares during the last quarter. Price T Rowe Associates Inc. MD increased its holdings in shares of Sionna Therapeutics by 30.4% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 831,373 shares of the company’s stock worth $34,203,000 after purchasing an additional 193,613 shares during the period. Finally, State Street Corp increased its holdings in shares of Sionna Therapeutics by 188.7% during the 4th quarter. State Street Corp now owns 693,395 shares of the company’s stock worth $28,526,000 after purchasing an additional 453,196 shares during the period.

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.